Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.

British drug maker GSK on Monday said it will buy US biopharmaceutical company IDRx for up to $1.15 billion. The Boston-based biotechnology firm is developing therapeutics for the treatment of ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

GSK on Monday also announced a $1 billion deal to acquire another privately held cancer drug developer, IDRx. The agreement ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.

(MENAFN) British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is ...

Major pharmaceutical companies like GSK, Eli Lilly, and Johnson & Johnson are engaging in multi-billion dollar acquisitions and deals during the JPMorgan Healthcare Conference in San Francisco. These ...

Subscribe to The Economic Times Prime and read the ET ePaper online.